The objective is to evaluate the long-term efficacy and the occurrence of vascular occlusion with second-generation BCR-ABL TKIs compared with imatinib in patients with CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.